O6-Benzylguanine

Phase 2Small molecule

NNational Cancer Institute (NCI)

O6-Benzylguanine is one of 348 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

347

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

HIV InfectionActive, not recruiting

LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Malignant GliomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

GliomaPreclinical

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Malignant GliomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 2

Active, not recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

O6-Benzylguanine

NNational Cancer Institute (NCI)

Phase 2

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Stem Cell

NCT05052957

Clinical

Trials by Indication[1]

Glioma5 trials

Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas

Completed·—·N/A·NCT00253487

Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma

Completed·—·Phase 1·NCT00006474

O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00275002·41 enrolled

Show 2 more trials

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

Completed·—·Phase 1·NCT00003348·56 enrolled

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

Completed·—·Phase 2·NCT00005081

Malignant Glioma4 trials

O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004892

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00669669·12 enrolled

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Terminated·PPediatric Brain Tumor Consortium·Phase 1·NCT00045721·3 enrolled

Show 1 more trial

O(6)-Benzylguanine in Treating Patients With Malignant Glioma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00002971

Glioblastoma Multiforme4 trials

S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00017147·183 enrolled

Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Withdrawn·—·Phase 2·NCT00046878

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00436436·12 enrolled

Show 1 more trial

BG & TMZ Therapy of Glioblastoma Multiforme

Completed·SStanton Gerson MD·Phase 1·NCT01269424·10 enrolled

Cutaneous T-cell lymphoma2 trials

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00961220·17 enrolled

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00003613·20 enrolled

Patients With Solid Tumors2 trials

O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery

Completed·UUniversity of Chicago·Phase 1·NCT00003766·25 enrolled

O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors

Completed·—·Phase 1·NCT00002604·28 enrolled

11 more indications

Lymphoma2 trials

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Withdrawn·FFred Hutchinson Cancer Center·N/A·NCT01769911

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated·—·Phase 1·NCT00003567·8 enrolled

Stem Cell1 trial

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Recruiting·LLeland Metheny·Phase 2·NCT05052957·16 enrolled

HIV infection1 trial

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT02343666

Metastatic Solid Tumors1 trial

Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00086970·32 enrolled

Soft Tissue Sarcoma1 trial

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

Completed·UUniversity of Chicago·Phase 2·NCT00005066·12 enrolled

Refractory1 trial

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003765·36 enrolled

Temozolomide1 trial

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00052780·72 enrolled

Metastatic Colorectal Cancer1 trial

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00005981·13 enrolled

Multiple Myeloma1 trial

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT00004072·17 enrolled

Solid Tumors1 trial

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00020150

Metastatic Melanoma1 trial

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00005961·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for O6-Benzylguanine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — O6-Benzylguanine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for O6-Benzylguanine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

O6-Benzylguanine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Glioma5 trials

Malignant Glioma4 trials

Glioblastoma Multiforme4 trials

Cutaneous T-cell lymphoma2 trials

Patients With Solid Tumors2 trials

Lymphoma2 trials

Stem Cell1 trial

HIV infection1 trial

Metastatic Solid Tumors1 trial

Soft Tissue Sarcoma1 trial

Refractory1 trial

Temozolomide1 trial

Metastatic Colorectal Cancer1 trial

Multiple Myeloma1 trial

Solid Tumors1 trial

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News